Lyssikatos Joseph P's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Nov 21, 2025
- Accession no.
- 0001967150-25-000007
- Filed
- Nov 21, 2025
- Trade date
- Nov 19, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $279.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyssikatos Joseph PCIK 0001967150 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2025 | Common Stock | SSaleDisposed | −12,008 | $22.30 | −$267,778.4 | 903,180 | Indirect | |
| Nov 19, 2025 | Common Stock | SSaleDisposed | −492 | $23.09 | −$11,360.28 | 902,688 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.